Screening of probiotic strains to improve visceral hypersensitivity in irritable bowel syndrome by using in vitro and in vivo approaches

E Torres-Maravilla; F A Carvalho; S Holowacz; J Delannoy; L Lenoir; E Jacouton; F Barbut; P Langella; L G Bermúdez-Humarán; A-J Waligora-Dupriet

doi:10.1163/18762891-bja00006

Screening of probiotic strains to improve visceral hypersensitivity in irritable bowel syndrome by using in vitro and in vivo approaches

Benef Microbes. 2024 Apr 30:1-18. doi: 10.1163/18762891-bja00006. Online ahead of print.

Authors

E Torres-Maravilla^{1

2}, F A Carvalho³, S Holowacz⁴, J Delannoy², L Lenoir⁴, E Jacouton⁴, F Barbut^{2

5}, P Langella¹, L G Bermúdez-Humarán¹, A-J Waligora-Dupriet²

Affiliations

¹ Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy-en-Josas, France.
² Université Paris Cité, INSERM, UMRS 1139, 3PHM, 75006 Paris, France.
³ INSERM U1107 NeuroDol, Université Clermont Auvergne, 3iHP, Clermont-Ferrand, France.
⁴ PiLeJe Laboratoire, 31-35 Rue de la Fédération, 75015 Paris, France.
⁵ Service de Microbiologie de l'environnement, UHLIN (Unité d'Hygiène et de Lutte contre les Infections Nosocomiales), National Reference Laboratory for Clostridium difficile, Groupe Hospitalier de l'Est Parisien (HUEP) Site Saint-Antoine, 75012 Paris, France.

PMID: 38677716
DOI: 10.1163/18762891-bja00006

Abstract

Oral administration of probiotics has been proposed as a promising biotherapy to prevent and treat different diseases related to gastrointestinal disorders, such as irritable bowel syndrome (IBS). Due to the increasing research area on the characterisation of new probiotic bacterial strains, it is necessary to perform suitable in vitro experiments, using pertinent cellular models, in order to establish appropriate readout profiles based on IBS symptoms and subtypes. In this work, a collection of 30 candidate strains, belonging mainly to the Lactobacillus and Bifidobacterium genera, were screened using three different sets of in vitro experiments with different readouts to identify promising probiotic strains with: (1) the ability to inhibit the synthesis of IL-8 production by TNF-α stimulated HT-29 cells, (2) immunomodulatory properties quantified as increased IL-10 levels in peripheral blood mononuclear cell (PBMCs), and (3) the ability to maintain epithelial barrier integrity by increasing the trans-epithelial/endothelial electrical resistance (TEER) values in Caco-2 cells. Based on these criteria, three strains were selected: Lactobacillus gasseri PI41, Lacticaseibacillus rhamnosus PI48 and Bifidobacterium animalis subsp. lactis PI50, and tested in a murine model of low-grade inflammation induced by dinitrobenzene sulfonic acid (DNBS), which mimics some of the symptoms of IBS. Among the three strains, L. gasseri PI41 improved overall host well-being by preventing body weight loss in DNBS-treated mice and restored gut homeostasis by normalising the intestinal permeability and reducing pro-inflammatory markers. Therefore, the potential of this strain was confirmed in a second murine model known to reproduce IBS symptoms: the neonatal maternal separation (NMS) model. The PI41 strain was effective in preventing intestinal permeability and reducing colonic hypersensitivity. In conclusion, the set of in vitro experiments combined with in vivo assessments allowed us to identify a promising probiotic candidate strain, L. gasseri PI41, in the context of IBS.